News

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks
Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...
Devdiscourse21h
Merck's Bold $3.9 Billion Bid on SpringWorks: A Game-Changer in Rare Cancer Therapies
Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...
BioSpace9h
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...
Devdiscourse3h
FDA Approvals, Global Business Moves, and Health News Highlights
The health sector is abuzz with significant news: from FDA approvals of novel drugs and mergers like Merck's acquisition of ...
pharmaphorum10h
Novartis grabs kidney drug developer Regulus in $1.7bn deal
Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...
Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting
Alphamab Oncology (stock code: 9966.HK) announced that the preclinical data on two novel bispecific antibody-drug conjugates (ADCs) JSKN021 and JSKN022 were presented as posters at the 2025 American ...